IRON Financial LLC Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

IRON Financial LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,169 shares of the biopharmaceutical company’s stock after purchasing an additional 268 shares during the period. IRON Financial LLC’s holdings in Gilead Sciences were worth $939,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Berkshire Bank grew its position in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 111 shares in the last quarter. Foundations Investment Advisors LLC boosted its stake in shares of Gilead Sciences by 27.0% in the fourth quarter. Foundations Investment Advisors LLC now owns 63,082 shares of the biopharmaceutical company’s stock valued at $5,827,000 after purchasing an additional 13,417 shares during the period. Valued Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 97.2% in the fourth quarter. Valued Wealth Advisors LLC now owns 629 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 310 shares in the last quarter. Pacer Advisors Inc. increased its stake in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after buying an additional 5,653,075 shares during the period. Finally, Cornerstone Wealth Group LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $200,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 456,234 shares of company stock valued at $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Mizuho upped their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. Finally, Bank of America reissued a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $95.35 on Tuesday. The business has a 50 day simple moving average of $91.74 and a 200-day simple moving average of $85.09. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market capitalization of $118.83 billion, a PE ratio of 1,059.44, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. Equities analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.23%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.